Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (12353)	11/28/1999 10:00:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

A tidbit more on the Overcoming Resistance Conference. Overcoming Resistance: New Strategies to Develop Antibiotics and Antifungals December 9 - 10, 1999 San Diego Marriott Hotel & Marina San Diego, CA The Biotechnology Division of the Institute for International Research is pleased to bring you the "Overcoming Resistance: New Strategies to Develop Antibiotics and Antifungals" conference. This comprehensive event fully explores the issues at hand within the anti-infective marketplace, as well as providing updates in trends and technologies. You directly benefit from the expertise of leaders within the biopharmaceutical industry who provide you with realistic strategies to quickly develop effective antibiotics, antifungals and antimicrobials. Learn how to redesign your discovery platforms to include the resistance factor and get solutions on how to overcome this ever-present problem. Hear from our panel of recognized industry leaders: Angela Nilius, ABBOTT LABORATORIES John F. Barrett, BRISTOL-MYERS SQUIBB Francis Tally, CUBIST PHARMACEUTICALS George Miller, MICROCIDE PHARMACEUTICALS Joyce Sutcliffe, PFIZER Charles Gluchowski, RIBOGENE, INC. Catherine Hardalo, SCHERING-PLOUGH Joaquim Trias, VERSICOR Stephen Carroll, XOMA CORP. Kenny Wong, MERCK Will the partner for Mycoprex be found among the other participants??